Clinical Trial Detail

NCT ID NCT04179864
Title A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Epizyme, Inc.
Indications

prostate small cell carcinoma

prostate neuroendocrine neoplasm

prostate adenocarcinoma

Therapies

Enzalutamide + Tazemetostat

Abiraterone + Prednisone + Tazemetostat

Age Groups: adult senior

No variant requirements are available.